Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: Prevalence, risk factors and virological outcome

Antiviral Therapy

Volumn 11, Issue 5, 2006, Pages 553-560

  Tozzi, Valerio ^a   Zaccarelli, Mauro ^a   Bonfigli, Sandro ^a   Lorenzini, Patrizia ^a   Liuzzi, Giuseppina ^a   Trotta, Maria Paola ^a   Forbid, Federica ^a   Gori, Caterina ^a   Bertoli, Ada ^a   Bellagamba, Rita ^a   Narciso, Pasquale ^a   Perno, Carlo Federico ^a   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EXPOSURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SALVAGE THERAPY; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 33747805631     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Center for HIV Medicine. AIDS 2000; 14:1545-1552.
2. Valdez H, Lederman MM, Woolley I, et al. Human immunodeficiency virus 1: protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med 1999; 159:1771-1776.
3. Lucas JM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87.
4. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
5. Ross L, Johnson M, DeMasi R, et al. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia. AIDS 2000; 14:813-819.
6. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16:1039-1044.
7. Hertogs K, Bloor S, Kemp SD, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000; 14:1203-1210.
8. Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001; 6 S3:25-44.
9. Johnson VA, Brun-Vezinet R Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med 2004; 12:119-124.
10. Zaccarelli M, Perno CE, Forbici F, et al. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis 2004: 38:433-437.
11. Ciancio BC, Trotta MP, Lorenzini P, et al. The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy. Antivir Ther 2003; 8:611-616.
12. Durant J, Clevenbergh P, Halfon R et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-2199.
13. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-93.
14. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-379:
15. Tural C, Ruiz L, Holtzer C, et al. Havana Study Group. Clinical utility of HIV-1 genotypine and expert advice: the Havana trial. AIDS 2002; 16:209-518.
16. Hirsch M, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2003; 37:113-128.
17. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as a part of treatment management: recommendations for the European setting. AIDS 2001; 15:309-320.
18. Department of Health and Human Services (DHHS). Rockville: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [updated 2004 Oct 29; cited 2005 Jan 5]. Available from: http://www.hivatis.org.
19. Kagan R, Winters M, Merigan T, Heseltine P. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res Hum Retroviruses 2004; 20:1-9.
20. Gallego O, de Mendoza C, Corral A, Soriano V. Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. AIDS 2004; 18:689-690.
21. Gallego O, Ruiz L, Vallejo A, Clotet B, Leal M, Soriano V. Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J Clin Microbiol 2002; 40:3865-3866.
22. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383-2388.
23. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186:181-188.
24. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:289-292.
25. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-571.
26. Iversen AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70:1086-1090.
27. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4:35-43.
28. Lennerstrand J, Stammers DK, Larder BA. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother 2001; 45:2144-2146.